Using 18F-FDG PET/CT imaging to detect breast cancer metastases
Improving Breast Cancer Staging With 18F-FDG PET/CT Imaging (The IMBRECAS PET Study)
This study is testing if a special type of imaging called 18F-FDG PET/CT can help find hidden breast cancer spread in patients with more advanced stages of the disease to see if it can change their treatment plans and improve their outcomes.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 300 (estimated) |
| Ages | 18 Years and up |
| Sex | Female |
| Sponsor | Vestre Viken Hospital Trust Academic / other |
| Locations | 1 site (Drammen) |
| Trial ID | NCT05730608 on ClinicalTrials.gov |
What this trial studies
This study investigates the effectiveness of 18F-FDG PET/CT imaging in identifying metastases in patients with stage II/III and locoregional recurrent breast cancer that may not be visible through conventional imaging methods like CT and bone scintigraphy. The primary objective is to determine if the use of this advanced imaging technique can lead to changes in disease staging and treatment decisions. Additionally, the study aims to assess overall survival and progression-free survival in patients whose staging is altered based on the PET/CT findings compared to those whose staging remains unchanged.
Who should consider this trial
Good fit: Ideal candidates for this study are women over 18 years old with high-risk primary or recurrent breast cancer who are not currently receiving treatment for other cancers.
Not a fit: Patients who are male, under 18 years old, pregnant, or have poor general health (ECOG status 3 or higher) may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could improve treatment decisions and outcomes for patients with advanced breast cancer by providing more accurate staging information.
How similar studies have performed: Other studies have shown promising results with advanced imaging techniques in cancer detection, suggesting potential for success in this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with high risk primary or recurrent breast cancer * Non pregnant women \> 18 years * Not receiving active treatment of other cancer types. * Eastern Cooperative Oncology Group (ECOG) status 0-2. Exclusion Criteria: * Pregnant woman * Males * Age under 18 * Patients receiving active treatment for other cancers * Poor general conditipon (ECOG 3 or higher)
Where this trial is running
Drammen
- Drammen Hospital - Vestre Viken HF — Drammen, Norway (Recruiting)
Study contacts
- Principal investigator: Harald Grut, MD, PHD — Vestre Viken Hospital Trust
- Study coordinator: Harald Grut, MD, PHD
- Email: harald.grut@gmail.com
- Phone: 004797108503
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.